Holen Sie sich die Stockscreener-App
25.05
2.04%
0.50
Handel nachbörslich:
25.05
Schlusskurs vom Vortag:
$24.55
Offen:
$24.92
24-Stunden-Volumen:
292.86K
Relative Volume:
0.76
Marktkapitalisierung:
$744.77M
Einnahmen:
$344.23M
Nettoeinkommen (Verlust:
$-24.16M
KGV:
-29.57
EPS:
-0.8471
Netto-Cashflow:
$28.33M
1W Leistung:
-0.87%
1M Leistung:
-15.29%
6M Leistung:
+8.82%
1J Leistung:
+26.64%
1-Tages-Spanne:
$24.57
$25.48
1-Wochen-Bereich:
$23.24
$26.02
52-Wochen-Spanne:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
25.05 | 729.90M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
494.54 | 182.60B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
190.79 | 134.18B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
564.66 | 44.63B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.54 | 32.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
299.89 | 29.21B | 3.17B | 642.63M | 516.49M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
CSTL PE Ratio & Valuation, Is CSTL Overvalued - intellectia.ai
Castle Biosciences, Inc.Common stock (NQ: CSTL - FinancialContent
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - stocktitan.net
Castle Biosciences CEO Maetzold sells shares worth $106,598 By Investing.com - in.investing.com
Castle Biosciences CEO Maetzold sells shares worth $106,598 - investing.com
Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options - stocktitan.net
Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs - stocktitan.net
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL) - Seeking Alpha
Castle Biosciences presents melanoma test data at AAD meeting By Investing.com - za.investing.com
Castle Biosciences Study Shows DecisionDx-Melanoma Test Enhances Risk Prediction Within AJCC Staging System - geneonline.com
Castle Biosciences presents melanoma test data at AAD meeting - Investing.com
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - Newswise
Derek Maetzold reports multiple Rule 144 sales — CSTL (CSTL) - stocktitan.net
Vanguard realigns reporting; holds 0% of Castle Biosciences (CSTL) - stocktitan.net
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Hedge Fund Moves: Can Castle Biosciences Inc deliver alpha2026 Top Decliners & High Return Trade Opportunity Guides - baoquankhu1.vn
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk - MarketBeat
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE StudySlideshow (NASDAQ:CSTL) 2026-03-23 - Seeking Alpha
Castle Biosciences Inc DecisionDx-Melanoma Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Valuation Update: Whats next for Castle Biosciences Inc stock2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Breakout Watch: Can Castle Biosciences Inc maintain its current growth rateMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
What are the future prospects of Castle Biosciences IncWeekly Stock Report & Risk Controlled Daily Plans - baoquankhu1.vn
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets - Yahoo Finance
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock By Investing.com - in.investing.com
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock - Investing.com
Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 18,650 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CEO sells 19,300 shares under 10b5-1 plan - Stock Titan
Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions - Traders Union
Castle Biosciences (CSTL) loses 16.8% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Risk Recap: What’s Castle Biosciences Inc.’s historical returnGold Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
Castle Biosciences (NASDAQ: CSTL) CEO sells 30,779 shares under 10b5-1 plan - Stock Titan
Big Picture: What is the implied volatility of Castle Biosciences IncQuarterly Trade Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Insider Sells $526,582.12 in Stock - MarketBeat
Castle Biosciences Officer Sells Shares - TradingView
Castle Biosciences (NASDAQ: CSTL) CCO sells 20,863 pre-planned shares - Stock Titan
Castle Biosciences (CSTL) Study Validates DecisionDx-Melanoma Te - GuruFocus
Castle Biosciences (CSTL) CEO sells 44,125 shares under 10b5-1 plan - Stock Titan
Prospective, Multi-center Study Published in Future - GlobeNewswire
New melanoma test flags patients who can skip lymph node biopsy - Stock Titan
CSTL (NASDAQ: CSTL) Form 144 shows proposed resale of 20,863 shares - Stock Titan
Derek Maetzold sells shares; CSTL (NASDAQ: CSTL) Form 144 lists large late‑2025 trades - Stock Titan
New study confirms sentinel lymph node prediction accuracy, Castle Biosciences asserts - Traders Union
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k - Investing.com Nigeria
Castle Biosciences Inc (CSTL) CFO Frank Stokes Sells 6,001 Shares - GuruFocus
Insider Selling: Castle Biosciences (NASDAQ:CSTL) CFO Sells 6,001 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Director Sells 7,403 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CFO sells 6,001 shares under 10b5-1 plan - Stock Titan
Castle Biosciences (CSTL) director exercises options and sells shares - Stock Titan
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest - GlobeNewswire
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):